Rani Therapeutics reports Q1 revenue of $1.7M, exceeding expectations by $1.2M amid strong contract growth.
Rani Therapeutics posted Q1 revenue of $1.7 million, a 900% year-over-year increase, beating estimates by $1.2 million. The company’s GAAP EPS of -$0.04 matched expectations, reflecting ongoing investment in growth initiatives.
Cash reserves stood at $43.4 million as of March 31, 2026, down from $49.7 million at the end of 2025. The decline aligns with planned spending to advance clinical programs and operational expansion.
The company did not disclose immediate market reactions, focusing on long-term pipeline development.